Campylobacter jejuni-Associated Hemophagocytic Lymphohistiocytosis and Guillain-Barre Syndrome: A Case Report.

Campylobacter jejuni (C. jejuni), a Gram-negative bacterium, belongs to microaerobic bacteria. We reported a 21-year-old male patient diagnosed with hemophagocytic lymphohistiocytosis (HLH) due to C. jejuni infection, who presented with multiple clinical manifestations of peripheral nerve injury, such as ophthalmoplegia, facial paralysis, and urinary retention during the treatment. Electromyography showed neurogenic injury and the final diagnosis was Guillain-Barre Syndrome (GBS). After treatment of dexamethasone combined with immunoglobulin, the patient was discharged from the hospital with partial recovery of neurological symptoms.

Exploratory COVID-19 death risk score based on basic laboratory tests and physiological clinical measurements.

BACKGROUND: In the event of a sudden shortage of medical resources, a rapid, simple, and accurate prediction model is essential for the 30-day mortality rate of patients with COVID-19. METHODS: This retrospective study compared the characteristics of the survivals and non-survivals of 278 patients with COVID-19. Logistic regression analysis was performed to obtain the "COVID-19 death risk score" (CDRS) model. Using the area under the receiver operating characteristic (AUROC) curve and Hosmer-Lemeshow goodness-of-fit test, discrimination and calibration were assessed. Internal validation was conducted using a regular bootstrap method. RESULTS: A total of 63 (22.66%) of 278 included patients died. The logistic regression analysis revealed that high-sensitivity C-reactive protein (hsCRP; odds ratio [OR]=1.018), D-dimer (OR=1.101), and respiratory rate (RR; OR=1.185) were independently associated with 30-day mortality. CDRS was calculated as follows: CDRS=-10.245+(0.022×hsCRP)+(0.172×D-dimer)+(0.203×RR). CDRS had the same predictive effect as the sequential organ failure assessment (SOFA) and "confusion, uremia, respiratory rate, blood pressure, and age over 65 years" (CURB-65) scores, with AUROCs of 0.984 for CDRS, 0.975 for SOFA, and 0.971 for CURB-65, respectively. And CDRS showed good calibration. The AUROC through internal validations was 0.980 (95% confidence interval [CI]: 0.965-0.995). Regarding the clinical value, the decision curve analysis of CDRS showed a net value similar to that of CURB-65 in this cohort. CONCLUSION: CDRS is a novel, efficient and accurate prediction model for the early identification of COVID-19 patients with poor outcomes. Although it is not as advanced as the other models, CDRS had a similar performance to that of SOFA and CURB-65.

Utilizing reclassification to explore characteristics and prognosis of KDIGOSCr AKI subgroups: a retrospective analysis of a multicenter prospective cohort study.

BACKGROUND: Acute kidney injury (AKI) is widespread in the intensive care unit (ICU) and affects patient prognosis. According to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, the absolute and relative increases of serum creatinine (Scr) are classified into the same stage. Whether the prognosis of the two types of patients is similar in the ICU remains unclear. METHODS: According to the absolute and relative increase of Scr, AKI stage 1 and stage 3 patients were divided into stage 1a and 1b, stage 3a and 3b groups, respectively. Their demographics, laboratory results, clinical characteristics, and outcomes were analyzed retrospectively. RESULTS: Of the 345 eligible cases, we analyzed stage 1 because stage 3a group had only one patient. Using 53 or 61.88 µmol/L as the reference Scr (Scrref), no significant differences were observed in ICU mortality (P53=0.076, P61.88=0.070) or renal replacement therapy (RRT) ratio, (P53=0.356, P61.88=0.471) between stage 1a and 1b, but stage 1b had longer ICU length of stay (LOS) than stage 1a (P53<0.001, P61.88=0.032). In the Kaplan-Meier survival analysis, no differences were observed in ICU mortality between stage 1a and 1b (P53=0.378, P61.88=0.255). In a multivariate analysis, respiratory failure [HR = 4.462 (95% CI 1.144-17.401), p = 0.031] and vasoactive drug therapy [HR = 4.023 (95% CI 1.584-10.216), p = 0.003] were found to be independently associated with increased risk of death. CONCLUSION: ICU LOS benefit was more prominent in KDIGOSCr AKI stage 1a patients than in stage 1 b. Further prospective studies with a larger sample size are necessary to confirm the effectiveness of reclassification.

Cobalt(II)-Based 3D Coordination Polymer with Unusual 4,4,4-Connected Topology as a Dual-Responsive Fluorescent Chemosensor for Acetylacetone and Cr2O72.

A cobalt(II) coordination polymer with an unusual 4,4,4-connected network was hydrothermally synthesized and observed with high thermal, solvent, and pH stabilities. This polymer can serve as the first dual-responsive fluorescent chemosensor for the selective detection of acetylacetone and Cr2O72- ion (pH 3.0) in aqueous systems.

{3,3'-Bis[(anthracen-9-yl)meth-yl]-1,1'-[(ethane-1,2-diyldi-oxy)bis-(ethane-1,2-di-yl)]bis-(imidazol-2-yl-idene)}mercury(II) bis-(hexa-fluoridophosphate) acetonitrile disolvate.

In the title compound, [Hg(C(42)H(38)N(4)O(2))](PF(6))(2)·2CH(3)CN, the Hg(II) cation lies on a twofold axis which is also the inter-nal symmetry element of the complete cationic complex. The Hg(II) cation is coordinated by two symmetry-related C(carbene) atoms [Hg-C = 2.058 (9) Å] in a nearly linear geometry, with a C-Hg-C angle of 175.8 (5)°. There are weak inter-molecular C-H⋯F inter-actions in the crystal packing between an F atom of a hexa-fluoridophosphate anion and a -CH(2)- group of the bis-N-heterocyclic carbene ligand.

Poly[[(1,10-phenanthroline)(µ-l-tartrato)zinc] hexa-hydrate].

The title compouand {[Zn(C(4)H(4)O(6))(C(12)H(8)N(2))]·6H(2)O}(n), has a linear chain structure parallel to [100] with Zn(C(4)H(4)O(6))(C(12)H(8)N(2)) repeat units; the asymmetric unit consists of one Zn(2+) cation, one l-tartrate dianion, one 1,10-phenanthroline and six free water mol-ecules. The Zn atom is in a distorted octa-hedral ZnN(2)O(4) coordination environment. The crystal structure is stabilized by O-H⋯O hydrogen bonds and π-π stacking of the phenanthroline units [centroid-centroid distances in the range 3.552 (2)-3.625 (2)Å] occurs between the chains. The title compound is isotypic with the Cu and Mn analogues.

Bis(2-propyl-1H-imidazol-3-ium) bis-(pyridine-2,6-dicarboxyl-ato-κO,N,O)cadmate(II).

The title salt, (C(6)H(11)N(2))(2)[Cd(C(7)H(3)NO(4))(2)], displays a discrete mononuclear structure, in which the central Cd(II) atom is six-coordinated in a distorted octa-hedral coordination geometry by two N and four O atoms from two different pyridine-2,6-dicarboxyl-ate anions in an O(2),N,O(6)-tridentate chelation mode. The crystal packing is stabilized by N-H⋯O hydrogen bonds and π-π inter-actions [centroid-centroid distance = 3.576 (5) Å].

[µ-1,4-Bis(1,2,4-triazol-1-ylmeth-yl)benzene]-bis-[aqua-(pyridine-2,6-dicarboxyl-ato)copper(II)] monohydrate.

The title compound, [Cu(2)(C(7)H(3)NO(4))(2)(C(12)H(12)N(6))(H(2)O)(2)]·H(2)O, displays a discrete dinuclear structure, in which the central Cu(II) atom is five-coordinated in a distorted square-based pyramidal coordination geometry and the flexible ligand 1,4-bis-(1,2,4-triazol-1-ylmeth-yl)benzene adopts a bis-monodentate bridging mode linking the Cu(II) atoms. It is further assembled by O-H⋯O hydrogen-bond inter-actions involving both the coordinated and uncoordinated water molecules. The latter exhibits half-occupancy.

Hexa-kis-(1-benzyl-1H-imidazole-κN)manganese(II) bis-(perchlorate).

In the title compound, [Mn(C(10)H(10)N(2))(6)](ClO(4))(2), the Mn(II) ion, located on an inversion center, is coordinated by six N atoms from three pairs of symmetry-related 1-benzyl-1H-imidazole ligands in a distorted octa-hedral geometry. In the crystal, weak inter-molecular C-H⋯O hydrogen bonds link the complex cations and perchlorate anions.

1,4-Bis[(1H-pyrazol-1-yl)meth-yl]benzene.

In the title compound, C(14)H(14)N(4), the center of the phenyl-ene group is a crystallographic center of inversion. The compound is composed of three aromatic rings displaying a Z-like conformation. The dihedral angle between the pyrazole rings and the central phenyl ring is 83.84 (9)°.

1,1'-[1,4-Phenyl-enebis(methyl-ene)]bis-(2-methyl-1H-imidazol-3-ium) 2,4-dicarb-oxy-benzene-1,5-dicarboxyl-ate monohydrate.

In the dication of the title compound, C(16)H(20)N(4) (2+)·C(10)H(4)O(8) (2-)·H(2)O, the dihedral angles formed by mean planes of the imidazolium rings and the benzene ring are 69.05 (18) and 89.1 (2)°. In the crystal, the components are linked into a three-dimensional network by inter-molecular N-H⋯O and O-H⋯O hydrogen bonds.

1,4-Bis(1H-benzimidazol-1-yl)but-2-ene.

In the pseudo-centrosymmetric mol-ecule of the title compound, C(18)H(16)N(4), two benzimidazole fragments form the dihedral angles of 83.49 (7) and 79.37 (7)°, with the mean plane of the linking butene chain. No classical inter-molecular inter-actions are observed. The porous crystal packing exhibits voids of 85 Å(3).

Aqua-(1H-benzimidazole-κN)(pyridine-2,6-dicarboxyl-ato-κO,N,O)copper(II) 0.75-hydrate.

The title complex, [Cu(C(7)H(3)NO(4))(C(7)H(6)N(2))(H(2)O)]·0.75H(2)O, consists of discrete monomeric units. The Cu(II) atom is coordinated by two carboxyl-ate O atoms and the N atom from a dipicolinate unit and by an N atom from a benzimidazole ligand. The distorted square-pyramidal geometry is completed by a longer axial bond to the O atom of a water mol-ecule. The mol-ecular structure and packing are stabilized by classical O-H⋯O and N-H⋯O hydrogen bonds, also including a disordered crystal water molecule.

N-Phenyl-N-(prop-2-en-1-yl)benzene-sulfonamide.

In the mol-ecule of the title compound, C(15)H(15)NO(2)S, the dihedral angle between the two phenyl rings is 41.8 (3)°. The S atom has a distorted tetra-hedral environment. In the crystal structure, C-H⋯O hydrogen bonds link the molecules into a ribbon-like structure along [010].

Piperazine-1,4-diium bis-(3,5-dicarboxy-benzoate).

The asymmetric unit of the title salt, C(4)H(12)N(2) (2+)·2C(9)H(5)O(6) (-), comprises one half of the piperazine-1,4-diium dication lying on an inversion centre and one 3,5-dicarboxy-benzoate anion. In the crystal, the ions are linked into a two-dimensional framework parallel to (101) by N-H⋯O and O-H⋯O hydrogen bonds.

3,3'-(p-Phenyl-enedimethyl-ene)di-1H-imidazol-1-ium bis-(4-nitro-benzoate)-4-nitro-benzoic acid (1/2).

The asymmetric unit of the title compound, C(14)H(16)N(4) (2+)·2C(7)H(4)NO(4) (-)·2C(7)H(5)NO(4), comprises one-half of the 3,3'-(p-phenyl-enedimethyl-ene)di-1H-imidazol-1-ium dication, which lies on an inversion centre, one 4-nitro-benzoate anion and one 4-nitro-benzoic acid mol-ecule. In the crystal, the components are linked into a two-dimensional network parallel to (110) by O-H⋯O, N-H⋯O and C-H⋯O hydrogen bonds.

Diaqua-bis(1,10-phenanthroline)magnesium dichromate(VI) 1,10-phenanthroline disolvate.

In the title compound, [Mg(C(12)H(8)N(2))(2)(H(2)O)(2)][Cr(2)O(7)]·2C(12)H(8)N(2), the cation and anion are situated on a twofold rotation axis. The Mg(II) ion is coordinated by four N atoms from two 1,10-phenanthroline ligands and two O atoms from coordinated water mol-ecules in a distorted octa-hedral geometry. Inter-molecular O-H⋯N and O-H⋯O hydrogen bonds and π-π inter-actions between the aromatic rings [shortest centroid-centroid separation = 3.527 (2) Å] link the cations, anions and 1,10-phenanthroline solvent mol-ecules into a hydrogen-bonded cluster.

4-Benzene-sulfonamido-benzoic acid.

In the mol-ecule of the title sulfonamide compound, C(13)H(11)NO(4)S, the dihedral angle between the planes of the benzene ring and the carboxyl substituent group is 6.7 (4)°. The two aromatic rings are inclined at 45.36 (15)° to one another. In the crystal, adjacent mol-ecules are linked via classical inter-molecular N-H⋯O and O-H⋯O, and non-classical C-H⋯O hydrogen bonds, which stabilize the crystal structure.

[3,3'-Bis(1-naphthylmethyl)-1,1'-(2,2'-oxy-diethyl-ene)bis-(imidazol-2-yl-idene)]mercury(II) bis-(hexa-fluorido-phosphate) acetonitrile solvate.

In the title compound, [Hg(C(32)H(30)N(4)O)](PF(6))(2)·CH(3)CN, the mercury(II) ion is coordinated by two carbene C atoms [Hg-C = 2.060 (6) and 2.066 (6) Å] and one ether O atom [Hg-O = 2.561 (5) Å] in a distorted T-shaped geometry with a C-Hg-C angle of 166.3 (3)°. One hexa-fluorido-phosphate anion is rotationally disordered between two orientations with an approximate ratio of 2:1. The crystal packing exhibits weak inter-molecular C-H⋯F and C-H⋯N inter-actions.

trans-Di-µ-carbonyl-bis-{carbon-yl[η-2,3,4,5-tetra-methyl-1-(2-thien-yl)cyclo-penta-dien-yl]ruthenium(I)}(Ru-Ru).

The title compound, [Ru(2)(C(13)H(15)S)(2)(CO)(4)], is a centrosymmetric binuclear metal-carbonyl complex containing an Ru-Ru single bond [2.7511 (8) Å]. Each Ru(I) atom is coordinated by two bridging carbonyl ligands, one terminal carbonyl ligand and one η(5)-cyclo-penta-dienyl group. The complex has a trans conformation and the two cyclo-penta-dienyl ring planes are parallel. The crystal structure involves weak C-H⋯O hydrogen bonds.